4 completed. 3 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
| Phase 3 | 1 | Completed 1 |
Follow HER2 peptide (369-377): new trials by email Literature Review of HER2 peptide (369-377) trials Research Report on HER2 peptide (369-377)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer Laboratory Biomarker Analysis, Nelipepimut-S Plus GM-CSF Vaccine, Sargramostim - Breast Ductal Carcinoma In Situ | Phase 2 | Completed | National Cancer Institute (NCI) | 43 | 2016-06-14 | 2023-12-05 |
| Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients NeuVax vaccine, Trastuzumab, GM-CSF - Breast Cancer | Phase 2 | Completed | Cancer Insight, LLC | 100 | 2014-10-01 | 2023-12-12 |
| Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax Herceptin, NeuVax vaccine, GM-CSF - Breast Cancer | Phase 2 | Completed | George E. Peoples | 275 | 2013-05-21 | 2020-12-02 |
| Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence NeuVax™ vaccine, Leukine® (sargramostim, GM-CSF) and water for injection - Breast Cancer With Low to Intermediate HER2 Expression | Phase 3 | Completed | Galena Biopharma, Inc. | 758 | 2011-11-01 | 2017-02-27 |
Breast Neoplasms (3) · Breast Neoplasms, Male (1) · Carcinoma, Intraductal, Noninfiltrating (1)
Cancer Insight, LLC (1) · Galena Biopharma, Inc. (1) · George E. Peoples (1) · National Cancer Institute (NCI) (1)
United States (4) · Bulgaria (1) · Canada (1) · Czechia (1) · France (1) · Germany (1) · Hungary (1) · Israel (1) · Poland (1) · Romania (1) · Russia (1) · Ukraine (1) · United Kingdom (1)
Elizabeth A Mittendorf, MD,FACS (1) · Powel H Brown (1)
N01CN00034 (1), P30CA016672 (1)